An Overview of Our Research
At the heart of CERTAINTY lies a sophisticated, multi-faceted approach to personalising treatment for blood cancer patients receiving CAR T cell therapies. Our methodology combines the power of computer simulations with real-world data and advanced biological analysis. We gather in-depth health records from patients over time and tap into detailed genetic and molecular information from individual cells. By integrating this information, we create virtual twins - digital replicas of patients’ unique biology - to understand how CAR T cells behave and interact at a very detailed level. This would allow us to predict how each patient might respond to therapy, helping doctors choose the most effective treatment path. Alongside this, we consider the broader human factors, such as social and healthcare system considerations, to make sure that our future virtual twins can be used effectively by healthcare professionals as a tool to support decision-making. All of this is built on a foundation of reliable software practices to ensure safety and accuracy in the medical field.
WP1 Project Management
WP2 Virtual Twin Data Integration & Management
WP3 Virtual Twin Prognostic & Predictive Modelling
WP4 Virtual Twin IT Architecture and Integration
WP5 Ex-Vivo and In-Vitro Characterisation of Patient-Derived Samples and Cell Products
WP6 The Virtual Twin in Real World Settings
WP7 Dissemination, Communication, and Exploitation
WP8 Ethics Requirements
Overall Methodology of CERTAINTY
Our Scientific Advisory Board
Clinical advice
University Hospital Centre Zagreb
Software as medical device
Berlin CERT
Digital twin for the human immune system
Université de Toulouse III - Paul Sabatier
Clinical advice
European Society for Blood and Marrow Transplantation
Science technology studies
University of Vienna
Clinical advice
European Society for Blood and Marrow Transplantation
AI trustworthiness & security
TÜVIT
What Our Coordinator Says
Dr. Kristin Reiche, Head of the Bioinformatics Unit at Fraunhofer IZI
"For CERTAINTY, we will build on existing computer-aided models of human biology. We want to combine these with novel models for genetically modified immune cells such as CAR T cells in order to model the individual course of disease and therapy for patients."